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S U M M A R Y
Objective: The hepatitis B vaccine was ﬁrst introduced into the routine immunization program in Henan
Province, China in 1992. In 2012, a survey was conducted to evaluate the protective effects of hepatitis B
vaccination for the populations born during the preceding 15 years.
Methods: A multistage stratiﬁed random cluster sampling method was used to collect samples. The
participants were interviewed and relevant information was obtained for the population aged 1 to
14 years using a standardized questionnaire; a 2- or 3-ml serum sample was taken from each participant
to measure hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Association and
logistic regression analyses were conducted to determine relationships between these parameters.
Results: A total of 13 207 residents aged 1 to 14 years residing in 60 villages or communities in Henan,
China were surveyed and had their blood collected. Serological analysis revealed that the HBsAg and
anti-HBc prevalences were 0.8% and 2.6%, respectively. The HBsAg prevalence among children under
5 years of age was 0.5%, showing a decline of 96% compared to the average national HBsAg prevalence in
1992. Children had a higher likelihood of HBsAg positivity if they had an HBsAg-positive family member
(odds ratio (OR) 4.26), no history of vaccination (OR 2.06), were born in a smaller township hospital or at
home (OR 1.61), were aged 10–14 years (OR 2.07), or were living in a rural area (OR 2.01).
Conclusions: The HBsAg prevalence rate in persons under 15 years of age has dropped signiﬁcantly in
Henan Province after two decades of vaccination. Thus millions of chronic HBV infections have been
prevented.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Hepatitis B often causes chronic infection and cirrhosis in
infected infants, children, and adults.1 Hepatitis B has become a
serious burden on the healthcare systems in many countries
because some patients infected with chronic hepatitis B develop
cirrhosis of the liver or liver cancer.2 In China, hepatitis B is the
most widely prevalent infectious disease.3
Henan Province is located in the middle of China and is the most
populous province among the 31 mainland China provinces and
municipalities. Henan has a population of nearly 97 million people.
This province also has the most patients with hepatitis B virus* Corresponding author. Tel./Fax: +86-371-68089026.
E-mail address: cdcgyh@163.com (G. Yonghao).
http://dx.doi.org/10.1016/j.ijid.2015.10.002
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(HBV) infection; according to a national survey conducted in
1992,4 there were nearly 8.5 million hepatitis B surface antigen
(HBsAg)-positive people in Henan Province, accounting for about
7% of the total number of HBsAg-positive patients in China.
In 1992 the Chinese government initiated a program in which
all newborn babies routinely received a hepatitis B vaccine in three
doses (at birth and at 1 and 6 months of age); however, all costs
associated with the vaccination were paid for by the infants’
families. In 2002, the hepatitis B vaccine was fully integrated into
the routine infant immunization program for newborns and the
vaccine costs were covered by public health funding (although
some vaccination costs were still paid by the infants’ families until
2005). As of 2012, this vaccination program had been in place in
Henan for 20 years and the ﬁrst cohort of children to receive the
vaccination had reached adulthood. In order to evaluate the
protective effects of vaccination, particularly in susceptibleciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Center for Disease Control and Prevention (HNCDC) conducted an
HBV serosurvey in Henan in 2012 on a large sample of the
population aged <15 years.
2. Methods
Planning for this study began in October 2011 and the data
analysis was completed in June 2013. All of the ﬁeld work was
conducted between May and June 2012.
2.1. Study population
The target population comprised local residents aged 1–14
years living in 60 investigation points in 18 cities. Henan has an
uneven socioeconomic distribution among the different geograph-
ic areas. Thus, a multistage stratiﬁed random cluster sampling
method was used. First, 159 districts and counties in Henan
Province were divided into three strata according to their level of
economic development in 2011: ‘high’ at GDP per capita $7000,
‘middle’ at GDP per capita $5000 to $6999, and ‘low’ at GDP per
capita <$5000. Each economic layer contained 53 districts and
counties, and 10 districts and counties were selected randomly
from each layer for analysis. Thus, a total of 30 districts and
counties were selected from the three layers, which contained
228 sub-districts and 306 townships in total. Second, based on the
population ratio of the urban to rural area (4:6), 24 sub-districts
and 36 townships were selected randomly from the 228 sub-
districts and 306 townships. Third, all of the communities and
villages of the 60 selected sub-districts and townships were
numbered, and 60 communities and villages were selected
randomly as the investigation points (Figure 1). Persons aged 1–
14 years who had been resident for more than 6 months as of the
time of the survey visit were selected.
2.2. Sampling method
The design effect coefﬁcient (Deff) was used to assess the sample
size. Using the expected HBsAg prevalence (P), Deff, and theFigure 1. Sampling ﬂow chart of the hepatitis B virus (HBV) epidemiological seromaximum permissible error (d) for the different age groups in the
study (P = 0.006, Deff = 1.5, and d = 0.0025 for age 1–4 years;
P = 0.01, Deff = 2.0, and d = 0.005 for age 5–9 years; P = 0.015,
Deff = 2.8, and d = 0.075 for age 10–14 years), the desired sample
size was 11 419 and included 5480 children aged <5 years,
3043 children aged 5–9 years, and 2896 children aged 10–14 years.
At least 92 children aged <5 years (5480/60), 51 children aged 5–9
years (3043/60), and 49 children aged 10–14 years (2896/60) at
each sample site were enrolled. If the target population size at one
sample site could not meet the average number needed for
statistical signiﬁcance, the remaining target population would be
collected from the nearest village/community.
2.3. Investigation
A house-to-house investigation was completed by trained staff
based on the sample list. An urban area was deﬁned as a region,
such as a county/city, that was the capital in the prefecture; rural
areas were those counties that were not the capital of the
prefecture. Through face-to-face interviews, the family was asked
questions about their child’s sex, date of birth, place of birth,
immunization history, and whether they had one or more family
members with hepatitis B conﬁrmed by a hospital. Immunization
status (vaccinated or not vaccinated) was recorded from the
child’s immunization certiﬁcate kept by the parents, or by a
review of the child’s immunization card kept at the township
hospital immunization clinic; if neither was available, the village/
community doctor’s registry was reviewed. If none of these
sources was available, the vaccination status was recorded as
unvaccinated.
2.4. Specimen collection
Blood samples were collected from each study participant, 3 ml
for children >2 years of age and 2 ml for children aged 2 years; on
the same day, the serum was separated in county laboratories and
stored at 20 8C. The serum samples were then transported and
stored at 20 8C at city laboratories within 1 week and submitted
to HNCDC.survey in Henan Province, central China (159 distracts and counties in total).
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All serum specimens were tested at HNCDC. A detailed
laboratory testing protocol was established before testing,
including the retesting of specimens with inconsistent results.
All of the samples were screened for HBsAg and total hepatitis B
core antibody (anti-HBc) using commercially-available enzyme-
linked immunosorbent assays (ELISA; Shanghai Kehua Bio-
engineering Co., Ltd, Shanghai, China). The tests were carried
out and interpreted in accordance with the manufacturer’s
instructions.
2.6. Statistical analysis
All data were entered into an Epi Data (v. 3.02) software
database twice and checked for consistency with the original
records. After verifying accuracy, the data were analyzed at HNCDC
using SPSS 17.0 software for Windows (SPSS Inc., Chicago, IL, USA).
Proportions and ratios were used to describe the socio-demo-
graphic characteristics of the participants and their infection status
regarding HBsAg positivity. The HBsAg and anti-HBc prevalences
were standardized according to the 2010 Henan population
structure. The Chi-square test was used to determine whether
associations were statistically signiﬁcant, and the level of
statistical signiﬁcance was set at p < 0.05. Multivariable logistic
regression was used to identify factors affecting the prevalence of
HBsAg in children aged 1–14 years; the dependent variable was the
prevalence of HBsAg. The independent variables assessed in this
study were having a family member with hepatitis B, traumatic
behaviors (including pedicure, ear-piercing, tattoo), a history of
surgery, a history of dental surgery, ethnicity (ethnic Han vs.
other), immunization history, location of the community (urban vs.
rural), place of birth (born in a hospital of a higher class than upper
third-class (mainly city hospitals) vs. born in a hospital with a
lower socioeconomic status (smaller township hospitals or at
home)), and age. Odds ratios (ORs) and their 95% conﬁdence
intervals (CI) were also calculated.Table 1
Demographic characteristics and HBV infection status of the study participants
Characteristic Test No. (%) HBsAg-posi
No. (%, 95%
Age (years)
1–4 5474 (41.4) 26 (0.5, 0.3
5–9 4407 (33.4) 32 (0.7, 0.5
10–14 3326 (25.2) 40 (1.2, 0.8
Total 13 207 (100) 98 (0.7, 0.6
Standardized ratea (0.8, 0.7–0.
Urban or rural
Urban 4917 (37.2) 19 (0.4, 0.2
Rural 8290 (62.8) 79 (1.0, 0.8
Sex
Male 7114 (53.9) 49 (0.7, 0.5
Female 6093 (46.1) 49 (0.8, 0.6
Ethnicity
Han 13 003 (98.5) 94 (0.7, 0.6
Other 204 (1.5) 4 (2.0, 0.1–
Birth locationb
Born in a higher-class hospital 7941 (60.1) 38 (0.5, 0.3
Born in a lower-class hospital 5236 (39.9) 60 (1.1, 0.8
Immunization status
Yes 12 715 (96.3) 87 (0.7, 0.6
No 492 (3.7) 11 (2.2, 0.9
HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B core antibody; CI, conﬁdence 
a Standardized rate: calculated according to the age composition of the population i
b Born in a lower-class hospital refers to those born in a third-class or other lower-cla
third-class hospitals.2.7. Ethical issues
The survey protocol conformed to the ethics guidelines of the
1975 Declaration of Helsinki and was approved by the Henan CDC
Medical Ethics Committee; all study work was performed in
accordance with national ethics regulations. Study participants or
their guardian were informed of the study purpose and of their
right to keep information conﬁdential. All of the survey results
were shared with the families.
3. Results
The survey investigated 13 510 subjects in total. Blood samples
were collected from 13 472 (99.7%) subjects, 13 443 (99.5%) of
whom also provided questionnaire information. The 29 (0.2%)
subjects who did not provide questionnaire information were
excluded from the study. Among the houses visited, 94.5% of the
occupants participated in the survey. Among these subjects, 13 207
(98.2%) were eligible for data analysis; 51 people were excluded
because the questionnaire contained incomplete information,
20 were outside the study age range, and 165 were excluded
because their serum samples were insufﬁcient or displayed severe
hemolysis.
3.1. Characteristics of the study population
The characteristics of the study population are shown in
Table 1. The male to female ratio was 1.16:1.
3.2. Results of HBV testing, distribution of HBV serological markers,
and immunization status
Among the children in the eligible study population, 98 were
positive for HBsAg (0.7%, 95% CI 0.6–0.8%) and 370 were positive
for anti-HBc (2.8%, 95% CI 2.5–3.0%). The standardized prevalences
adjusted to represent the Henan population age 1–14 years were
0.8% for HBsAg and 2.6% for anti-HBc.tive
 CI)
p-Value Anti-HBc-positive
No. (%, 95% CI)
p-Value
–0.7) <0.01 126 (2.3, 1.9–2.7) <0.01
–1.0) 110 (2.5, 2.0–3.0)
–1.6) 134 (4.0, 3.3–4.7)
–0.8) 370 (2.8, 2.5–3.0)
9) (2.6, 2.5–2.7)
–0.6) <0.01 95 (1.9, 1.5–2.3) <0.01
–1.2) 275 (3.3, 2.9–3.7)
–0.9) 0.44 174 (2.4, 2.0–2.8) <0.01
–1.0) 196 (3.2, 2.8–3.6)
– 0.8) 0.04 356 (2.7, 2.4–3.0) <0.01
4.0) 14 (6.9, 3.4–10.4)
–0.7) <0.01 176 (2.2, 1.9–2.5) <0.01
–1.4) 194 (3.7, 3.2–4.2)
–0.8) <0.01 340 (2.7, 2.4–3.0) <0.01
–3.5) 30 (6.1, 4.0–8.0)
interval.
n the 2010 demographic information of Henan.
ss hospital or at home. Born in a higher-class hospital refers to those born in above
Table 2
Immunization status of the study participants aged <15 years in Henan Province
Ages
(years)
Yes 95% CI Total
Frequency Percentage
1–4 5396 98.6 98.3–98.91 5474
5–9 4234 96.1 95.5–96.7 4407
10–14 3085 92.8 91.9–93.7 3326
Total 12 715 96.3 96.0–96.6 13 207
CI, conﬁdence interval.
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steadily from 0.5% (95% CI 0.3–0.7%) among children aged 1–4
years to 1.2% (95% CI 0.8–1.6%) among children aged 10–14 years
(Table 1). Differences in prevalence were highly signiﬁcant for the
three 5-year age groups, but there was no difference between the
1–4 and 5–9 years age groups (p = 0.10). The association between
the increased prevalence of anti-HBc positivity and the increase in
age was similar to the trend observed for HBsAg positivity.
HBsAg prevalence was higher for females (0.8%, 95% CI 0.6–
1.0%) than males (0.7%, 95% CI 0.5–0.9%) (Table 1), but the
difference was not signiﬁcant (p = 0.44). The HBsAg prevalence
among persons living in urban areas (0.4%, 95% CI 0.2–0.6%) was
lower than among persons living in rural areas (1.0%, 95% CI 0.8–
1.2%, p < 0.01). The prevalence of anti-HBc showed the same trend.
Among the 98 HBsAg-positive persons, 96 (98.0%, 95% CI 95.6–
100%) were anti-HBc-positive and two (2.0%, 95%CI, 0–4.8%) were
anti-HBc-negative.
Table 2 shows that the vaccination rate declined with
increasing age. The vaccine coverage was signiﬁcantly lower in
the older age groups. The average vaccination rate was 96.3% (95%
CI 96.0–96.6%).
3.3. Multivariable analysis of HBsAg status for children
Single-factor analysis was carried out for nine possible risk
factors, including having one or more family members with
hepatitis B, traumatic behavior, history of surgery, and history of
dental surgery (Table 3). Six risk factors were related to HBV
infection (Table 3). Further analysis by multivariate analysis
showed that ﬁve of the risk factors listed in Table 3 were
signiﬁcantly related to HBV infection. The results of the
multivariate analysis showed that if a child had an HBsAg-positive
family member (OR 4.26), was unvaccinated (OR 2.06), and livingTable 3
Multivariable analysis of associated possible risk factors for HBsAg seroprevalence am
No. Risk factors Response To
1 Has a family member with hepatitis B Yes 
No 12
2 Traumatic behavior Yes 
No 12
3 History of surgery Yes 
No 12
4 History of dental surgery Yes 
No 12
5 Ethnic Han Yes 12
No 
6 No immunization history Yes 
No 12
7 Lives in a rural area Yes 
No 
8 Born in a third-class or other lower-class hospital Yes 
No 
9 >10 years old Yes 
No 
OR, odds ratio; CI, conﬁdence interval.
a Single-factor analysis results showed an association with HBV infection.in a rural area (OR 2.01), that child had a higher likelihood of HBsAg
positivity than a child who did not have a family member with
hepatitis B, who had been vaccinated, and who lived in an urban
area (p < 0.05; Table 3). Children born in more sophisticated
hospitals had the beneﬁt of a reduced prevalence of HBsAg, while
those born in smaller township hospitals or at home had a
successively higher likelihood of HBsAg positivity (OR 1.61).
Children aged 10–14 years had a higher prevalence of HBsAg
positivity than children aged 1–9 years (OR 2.07; p < 0.01; Table 3).
4. Discussion
HBV infection and its sequelae have been recognized globally as
serious problems. Worldwide, over 350 million individuals were
reported to be chronically infected with HBV in 2006.5 The
Western Paciﬁc region is disproportionately affected by HBV, with
over half of all deaths caused by this infection occurring in this
region, despite having only around 28% of the global population. As
estimated in 2002, of the 278 000 HBV-related deaths in the region
each year, over 90% are due to chronic infections acquired decades
earlier at birth or during early childhood.6,7
Thus far, three national HBV serological surveys have been
conducted in China: one in 1979, the second in 1992, and the third
in 2006.4,8 According to the 1992 national survey, the average rate
of HBsAg positivity in the Chinese population was about 10%.
Furthermore, this prevalence reached 9.67% in children under
5 years of age. In China, one survey showed that for children born
during the period 1992–2001, the rates of three-dose and timely
birth dose coverage with hepatitis B vaccine were 50.6% and 35.1%,
respectively. For children born during 2002–2005, the rates of three-
dose and timely birth dose coverage with hepatitis B vaccine had
increased to 89.4% and 73.4%, respectively, and these reached 93.4%
and 82.6%, respectively, for children born in 2005.9 The national HBV
serological survey conducted in 2006 showed that children under
5 years of age had an infection rate of 1.0%, a decline of 90% compared
to the infection rate in 1992. This decline is most likely attributable
to the increase in immunization coverage ratios after 2002.
Even within the same country, the modes of transmission of
HBV vary between different regional, sex, and age groups.1,2,10,11
Additionally, because there are different levels of economic
development in east, south, north, west, and central China, the
effects of the implementation of immunization programs among
the different provinces may not be consistent. This may lead toong children aged <15 years in Henan, China
tal No. (%) Positive No. (%) p-Value OR 95% CI for OR
304 (2.3) 8 (2.6) <0.01a 4.26 2.03–8.91
 903 (97.7) 90 (0.7) 1
998 (7.6) 7 (0.7) 0.38 0.73 0.35–1.49
 209 (92.4) 91 (0.7) 1
667 (5.1) 4 (0.6) 0.64 0.79 0.29–2.18
 540 (94.9) 94 (0.8) 1
1192 (9.0) 6 (0.5) 0.31 0.64 0.28–1.50
 015 (91.0) 92 (0.8) 1
 303 (98.5) 94 (0.7) 0.09a 0.41 0.15–1.13
204 (1.5) 4 (2.0) 1
492 (3.7) 11 (2.2) 0.03a 2.06 1.07–4.00
 715 (96.3) 87 (0.7) 1
8294 (62.8) 79 (1.0) 0.01a 2.01 1.16–3.48
4913 (37.2) 19 (0.4) 1
5236 (39.7) 60 (1.1) 0.04a 1.61 1.03–2.53
7941 (60.3) 38 (0.5) 1
3327 (25.2) 58 (1.7) <0.01a 2.07 1.34–3.20
9880 (74.8) 40 (0.4) 1
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different target populations in different provinces.
The present data showed that the HBsAg prevalence in children
aged 1–4 years was 0.5%. This value is markedly lower than that
recorded in the national HBV sero-epidemiological surveys
conducted in 1992 and 2006. It is also lower than that reported
for other regions of China and other counties. One survey reported
in 2009 showed that the HBsAg prevalence rate in children aged 0–
5 years was 0.96% in Zhejiang Province, China in 2007.12 In
2012 and 2014, other surveys in Guangdong and Ganshu showed
the HBsAg prevalence rate to be 1.99% and 1.3%, respectively, in the
same age group in 2010.13,14 As reported in 2015, the HBsAg
prevalence in 2012 was 2.3% in children aged 4–6 years in Papua
New Guinea, where the hepatitis B vaccine was introduced for all
infants starting in 1989, with the inclusion of a birth dose in 1992,
but with low vaccine coverage (60–70% HepB3, 20–30% timely
birth dose).15 In 2014, Laos, where a phased HBV vaccine was
introduced into the national immunization schedule from 2001,
reported that the HBsAg prevalence was 4.6% in pre-school
children in 2011.16 In 2015, Nigeria, where the vaccination
programs have not received adequate attention or funding by
the government until now, reported that the prevalence of HBsAg
in that country was 11.5% in children.17
In contrast, some regions and counties have reported a lower
prevalence of HBsAg compared to Henan Province. In 2010, Wu
et al. did not ﬁnd any HBsAg-positive sample among those
obtained from 221 randomly selected children aged 0–5 years in
Beijing; this may have been due to the small sample size.18 Anhui
Province, located in the middle of China and adjoining Henan
Province, reported in 2012 that the HBsAg prevalence was 0.3% in
children aged 0–5 years in 2006.19 In 2013 and 2015, Singapore (all
newborns received hepatitis B vaccine from September 1, 1987)
and Fiji (hepatitis B vaccine was introduced into the childhood
immunization program in 1989) did not ﬁnd any HBsAg-positive
children under 7 years of age in 2010 and 2009, respectively.20,21 In
2013, Korea, where universal vaccination of all infants has been
performed since 1991, reported that the prevalence of HBsAg in
children aged 10–19 years was 0.1% in 2010.22 Obviously, the data
listed above show that the earlier the immunization program was
carried out in an area, the lower the HBsAg prevalence that was
achieved in that area. More encouragingly, the prevalence of HBsAg
among children aged 5–9 and 10–14 years in Henan Province has
also decreased dramatically compared to the same age groups in
China in 1992 and in 2006. In these cohorts, an estimated 2–3
million HBV carriers and 0.35–0.53 million future HBV-related
deaths have been prevented.7
There were signiﬁcant differences in the HBsAg-positive rate
between children who lived in urban and rural areas of Henan
Province. The HBsAg-positive rate in the rural population under
15 years of age was higher than that in the urban population. Other
studies in China have also indicated that the rural areas often have
the highest HBsAg prevalence.1,3,8,9 Previous studies have reported
that immunization coverage has often remained low in rural areas
of China and that children born in rural areas are more likely not to
receive a timely birth dose or full immunization.13 In addition,
women of childbearing age in rural areas are more likely to be
HBsAg- and hepatitis B e antigen (HBeAg)-positive than women in
urban areas. This may increase the rate of transmission of HBV
infection from mother to child in rural areas.23
Previous studies in China have reported that males often have
higher HBV infection rates than females, and the difference has
been reported as signiﬁcant.24–26 The signiﬁcantly different rates
of infection between males and females in China are often related
to the entire population. The reasons for male adults having a
higher HBV prevalence may be due to societal differences, such as
more unsafe habits related to HBV infection for men, for exampleshaving in the barber shop.14,24,26 The present results and the data
of Shen et al. show that the difference in HBV prevalence between
male and female children was not signiﬁcant, especially among
those covered by the universal vaccination program.27 The slight
difference between male and female children in this study may be
due to random errors during the selection of samples and
serological detection.
The multivariate analysis provided useful insights into the risk
factors for HBsAg positivity among children. The main risk factors
for HBsAg positivity, in addition to a lack of vaccination, included
birthplace (a predictor of health care and immunization access),
age, place of residence, and whether the child had a family member
with hepatitis B. Infants born in higher-level hospitals are much
more likely to receive a birth dose of HepB (hepatitis B vaccine)
than those born in lower-level hospitals or at home.10,28 In
addition, in larger hospitals, mothers may be screened for HBsAg,
and the infants of those mothers found to be positive may also be
given HBIG (hepatitis B hyper-immune globulin). The hepatitis B
vaccine has been offered free of charge to the general population in
Henan since 2002, a period of exactly 10 years. Not surprisingly,
the survey results showed that children aged 0 to 10 years had a
low risk related to HBV infection compared to children aged 11–14
years. These data indicate that the free vaccine policy may have
signiﬁcantly enhanced the vaccination rate of newborns in Henan.
One study limitation is that study participation was limited to
persons who had been resident in the surveillance points for
6 months or more; those children who had only been in the region
for a short time were excluded. This would include children who
had followed their migrant parents for a short work or study period
and unregistered children born outside of family planning. As the
majority of these children come from poorer, rural areas, they may
have had a relatively high prevalence of HBsAg and lower
likelihood of hepatitis B vaccination. Therefore, the data may
underestimate the overall HBsAg prevalence. In addition, 452 sub-
jects had to be disqualiﬁed from the sample list for health reasons
(cerebral palsy, immunodeﬁciency, blood syncope, and hemodial-
ysis patients) and 2.2% of the people who had originally agreed to
participate in the survey did not attend the scheduled interviews.
Exact vaccination doses/dates were not surveyed. Thus, some of
the subjects in this study who had been vaccinated may have
received an incomplete vaccination. In other words, they may have
received one or two doses or their ﬁrst vaccination was delayed.
Since the ﬁrst vaccination dose is very important for stopping HBV
infection in children, these children may have been infected with
HBV. In this study, these factors may increase the rate of HBV
infection in the vaccinated population.
In conclusion, after two decades of vaccination, the HBsAg
prevalence rate in persons under 15 years of age has dropped in
Henan Province compared to the average HBsAg-positive ratio of
China in 1992, meeting the goal set by the Chinese government (an
HBsAg prevalence rate of less than 1% in children under 5 years old
by 2010) and the World Health Organization (an HBsAg prevalence
rate of less than 1% in children less than 5 years old in the Asia-
Paciﬁc region by 2017). It was not possible to calculate the accurate
decline ratio of HBsAg in persons under 15 years of age in Henan,
China from 1992 to 2012 because these historical data were
absent. As the ﬁrst large sample size epidemiological serosurvey of
HBV in persons under 15 years old in Henan, this study provides a
baseline for other studies. These data suggest that free immuniza-
tion programs for infants should continue to be made available and
that each newborn should be immunized shortly after birth. In
addition, in order to reduce the prevalence of HBsAg in the whole
population, it is necessary to improve the care and treatment of
chronic patients and to ﬁnd and treat acute infectious patients as
soon as possible. Finally, it is necessary to greatly improve the
health education in rural areas to control HBV infection.
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